AI assistant
Tempest Therapeutics, Inc. — Director's Dealing 2014
Dec 11, 2014
34632_dirs_2014-12-11_2637a8bc-66ce-4df0-9cd3-ac0c145c09fe.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2014-12-09
Reporting Person: McNeely Theresa (EVP, Chief Comm. Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $5.48 | 2022-09-07 | Common Stock (58000) | Direct | |
| Stock Option (right to buy) | $9.00 | 2023-01-29 | Common Stock (15000) | Direct | |
| Stock Option (right to buy) | $14.00 | 2023-06-07 | Common Stock (20000) | Direct | |
| Stock Option (right to buy) | $10.09 | 2024-03-05 | Common Stock (35000) | Direct |
Footnotes
F1: The option vests as to 25% of the shares on August 21, 2013 and vests as to an additional 6.25% of the shares at the end of each successive three-month period thereafter.
F2: The option vests as to 25% of the shares on January 1, 2014 and vests as to an additional 6.25% of the shares at the end of each successive three-month period thereafter.
F3: The option vests as to 25% of the shares on June 7, 2014 and vests as to an additional 6.25% of the shares at the end of each successive three-month period thereafter.
F4: The option vests as to 25% of the shares on March 5, 2015 and vests as to an additional 6.25% of the shares at the end of each successive three-month period thereafter.